Talima Therapeutics

Talima Therapeutics is dedicated to developing innovative therapeutic solutions targeting unmet medical needs, focusing on enhancing patient care through advanced biomedical technologies. Founded in 2004, Talima Therapeutics is based in Santa Clara, US, specializing in therapeutic innovations. The company has undergone strategic pivots to adapt to market changes. It has successfully raised a total of USD 8.

020 mn across funding rounds, with the latest being a Series B round featuring prominent investors like De Novo Ventures and Palo Alto Healthcare. The current valuation of the company stands at USD 21. 324 mn. Talima Therapeutics focuses on delivering innovative therapeutic solutions.

Its offerings emphasize patient-centered care, addressing specific health challenges through advanced biomedical applications. The company's primary customer base includes healthcare providers and institutions, utilizing these solutions to meet diverse patient needs. Talima Therapeutics generates revenue through structured partnerships and direct sales to healthcare providers. The transaction model includes subscription-based services for its therapeutic solutions, allowing clients to engage in annual contracts that cover licensing and support, thereby facilitating integration into existing healthcare systems.

Talima Therapeutics plans to enhance its product offerings and expand its reach into new markets. However, as of now, the company has ceased operations and is no longer pursuing growth initiatives.